Matthew Hebden Porteus is Sutardja Chuk Professor of Definitive and Curative Medicine at Stanford University.[1] In 2003, as a postdoctoral fellow in David Baltimore's lab at the California Institute of Technology, Porteus was the first to demonstrate precise gene editing in human cells using chimeric nucleases.[2]
He graduated magna cum laude from Harvard University and completed his MD and PhD at Stanford University.[3] For his post-doctoral work he trained with David Baltimore at MIT and Caltech.[3] He is a scientific founder of CRISPR Therapeutics and an academic founder of Graphite Bio.[4][5]
He has an h-index of 69 according to Google Scholar.[6]
References
edit- ^ "Matthew Porteus". Stanford University School of Medicine. Retrieved 23 June 2021.
- ^ Porteus MH, Baltimore D (May 2003). "Chimeric nucleases stimulate gene targeting in human cells". Science. 300 (5620): 763. doi:10.1126/science.1078395. PMID 12730593. S2CID 34460337.
- ^ a b "Dr. Matthew Porteus". CRISPR Therapeutics. Retrieved 23 June 2021.
- ^ "There Are Now Two Pushes to Treat Sickle Cell Disease With CRISPR". CRISPR Medicine News. Retrieved 26 June 2021.
- ^ "About Us: Academic Founders". Graphite Bio. Retrieved 26 June 2021.
- ^ "Matthew Porteus". Google Scholar. Retrieved 28 October 2023.
External links
edit- Matthew Porteus publications indexed by Google Scholar
 | This biographical article about a scientist is a stub. You can help Wikipedia by expanding it. |